130 related articles for article (PubMed ID: 9313603)
1. Mibefradil, a novel calcium antagonist, in elderly patients with hypertension: favorable hemodynamics and pharmacokinetics.
Bursztyn M; Kadr H; Tilvis R; Martina B; Oigman W; Talberg J; Kobrin I
Am Heart J; 1997 Aug; 134(2 Pt 1):238-47. PubMed ID: 9313603
[TBL] [Abstract][Full Text] [Related]
2. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.
Oparil S; Kobrin I; Abernethy DR; Levine BS; Reif MC; Shepherd AM
Am J Hypertens; 1997 Jul; 10(7 Pt 1):735-42. PubMed ID: 9234827
[TBL] [Abstract][Full Text] [Related]
3. The addition of mibefradil to chronic hydrochlorothiazide therapy in hypertensive patients is associated with a significant antihypertensive effect.
Carney S; Wing L; Ribeiro A; Kallwellis R; Zimlichman R; Viskoper RJ; Mion D; Kobrin I
J Hum Hypertens; 1997 Jul; 11(7):459-66. PubMed ID: 9283064
[TBL] [Abstract][Full Text] [Related]
4. Antihypertensive effects of mibefradil in the treatment of mild-to-moderate systemic hypertension.
Oparil S; Bernink P; Bursztyn M; Carney S; Kobrin I
Am J Cardiol; 1997 Aug; 80(4B):12C-19C. PubMed ID: 9286849
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group.
Bernink PJ; Prager G; Schelling A; Kobrin I
Hypertension; 1996 Mar; 27(3 Pt 1):426-32. PubMed ID: 8698449
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and tolerability of two long-acting calcium antagonists, mibefradil and amlodipine, in essential hypertension. Mibefradil Hypertension Study Group.
Karch FE; Pordy R; Benz JR; Carr A; Lunde NM; Marbury T; Tarro JN
Clin Ther; 1997; 19(6):1368-78. PubMed ID: 9444446
[TBL] [Abstract][Full Text] [Related]
7. Comparative antihypertensive effectiveness of once-daily mibefradil and diltiazem CD. Mibefradil Hypertension Study Group.
Bittar N
Clin Ther; 1997; 19(5):954-62. PubMed ID: 9385483
[TBL] [Abstract][Full Text] [Related]
8. Antihypertensive effects of mibefradil: a double-blind comparison with diltiazem CD.
Massie BM; Chrysant SG; Jain A; Weir M; Weiss R; Korrin I
Clin Cardiol; 1997 Jun; 20(6):562-8. PubMed ID: 9181268
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy and safety of losartan (50-100 mg) with the T-type calcium channel blocker mibefradil (50-100 mg) in mild to moderate hypertension.
Chung O; Hinder M; Sharma AM; Bönner G; Middeke M; Platon J; Unger T
Fundam Clin Pharmacol; 2000; 14(1):31-41. PubMed ID: 10681072
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients.
Höglund C; Cifkova R; Mimran A; Tenczer J; Watt A; Wilkins MR; Lindberg E
Cardiology; 1998 May; 89(4):263-70. PubMed ID: 9643273
[TBL] [Abstract][Full Text] [Related]
11. Mibefradil, a pharmacologically distinct calcium antagonist.
Ernst ME; Kelly MW
Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
[TBL] [Abstract][Full Text] [Related]
12. Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist.
Kobrin I; Charlon V; Lindberg E; Pordy R
Am J Cardiol; 1997 Aug; 80(4B):40C-46C. PubMed ID: 9286853
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the safety and efficacy of mibefradil and nifedipine SR in patients with renal disease and hypertension.
Woittiez AJ; Huysmans FT; Bailey R; Robson RA; Mion Júnior D; Villa G; Kobrin I
Clin Nephrol; 1998 Mar; 49(3):160-6. PubMed ID: 9543597
[TBL] [Abstract][Full Text] [Related]
14. Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists.
Massie BM; Lacourcière Y; Viskoper R; Woittiez A; Kobrin I
Am J Cardiol; 1997 Aug; 80(4B):27C-33C. PubMed ID: 9286851
[TBL] [Abstract][Full Text] [Related]
15. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group.
Bakx AL; van der Wall EE; Braun S; Emanuelsson H; Bruschke AV; Kobrin I
Am Heart J; 1995 Oct; 130(4):748-57. PubMed ID: 7572582
[TBL] [Abstract][Full Text] [Related]
16. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.
Braun S; van der Wall EE; Emanuelsson H; Kobrin I
J Am Coll Cardiol; 1996 Feb; 27(2):317-22. PubMed ID: 8557900
[TBL] [Abstract][Full Text] [Related]
17. A randomised, double-blind trial comparing mibefradil and amlodipine: two long-acting calcium antagonists with similar efficacy but different tolerability profiles. Mibefradil International Study Group.
Viskoper RJ; Bernink PJ; Schelling A; Ribeiro AB; Kantola IM; Wilkins MR; Kobrin I
J Hum Hypertens; 1997 Jun; 11(6):387-93. PubMed ID: 9249234
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure.
van der Vring JA; Bernink PJ; van der Wall EE; van Velhuisen DJ; Braun S; Kobrin I
Clin Ther; 1996; 18(6):1191-206. PubMed ID: 9001836
[TBL] [Abstract][Full Text] [Related]
19. Steady-state trough plasma mibefradil concentrations and correlation to blood pressure response in hypertensive patients with chronic renal disease.
Pordy R; Woittiez A
Int J Clin Pharmacol Res; 1998; 18(3):105-8. PubMed ID: 9825266
[TBL] [Abstract][Full Text] [Related]
20. Differential properties of mibefradil in hypertension and angina.
Kobrin I
J Hypertens Suppl; 1997 Dec; 15(5):S33-40. PubMed ID: 9481614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
